On Jun. 8, 2018, the U.S. Centers for Disease Control and Prevention (CDC) published Immunization Practices Advisory Committee (ACIP)’s recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4) in the 2018-19 influenza season.

Quadrivalent live attenuated influenza vaccine (LAIV4) (FluMist Quadrivalent, MedImmune) has been licensed in the United States since 2012 and was first available during the 2013–14 influenza season, replacing LAIV3.